Stinging insect hypersensitivity: a practice parameter update 2011.

These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing "Stinging insect hypersensitivity: a practice parameter update II." Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters.

Insect sting allergy.

Insect sting allergy has served as an excellent model for the allergic process over the past century. In particular, during the last 30 years, a new form of diagnostic testing and treatment with vo m has been one of the great suc-cess stories in the entire field of allergy. VIT reduces the risk of recurrent life-threatening reactions from about 60% to less than 2%.

Managing insect sting allergy. The ins and outs of venom immunotherapy.

Insect sting allergy can lead to severe, even fatal, reactions in susceptible persons. Although self-injection epinephrine often terminates the reaction, it is not always effective. In this article, Dr Graft explores the use of venom immunotherapy (VIT) in selected patients in whom successful treatment can produce psychosocial as well as physiologic benefits.

Maintenance venom immunotherapy.

Purpose Of Review: Venom immunotherapy has proven to be a very effective method for the prevention of future re-sting reactions. However, initiation of the venom injection program is just the beginning. This review looks at recent papers which shed light on other issues that arise during maintenance venom immunotherapy.